Toggle menu

Emma Moatt

Research Project Manager

Emma Moatt

Before Emma’s career within the research field, she initially aimed to become a Health Promotion Officer. Her interest in health promotion was sparked by a module in her undergraduate degree, where she conducted an analysis on health equalities displayed among different areas of living. She later completed her undergraduate dissertation on ‘the health behaviours of different religious groups’. For this, she conducted face-to-face interviews with Christians, Muslims and Hindus, to identify their motivations and current practice of the following health behaviours; healthy eating, exercise, smoking tobacco and alcohol intake. Emma then went on to complete an MSc in Health Promotion at Kings College London where her interests developed further in nightclub health promotion, social marketing and health inequalities.

Emma then moved up to Edinburgh and applied her knowledge into practice by undertaking a variety of health promoting roles; being a volunteer for the Pilton Community Health Project, Development Worker for a healthy eating charity, healthy eating educator for after school clubs, and then becoming a full time Community Development Worker for NHS Lothian. These roles allowed Emma to develop her skills in running group classes, conducting health needs assessments, and providing one-to-one support within the community. However, due to funding in this department being reduced, Emma came off her health promotion path and instead took the opportunity to step into the clinical research field.

In January 2017, Emma became the Research Administrator for EMERGE, and this is where she caught the Emergency Department (ED) research bug! She found working as part of the wider ED team a fascinating place to be, due to the unpredictable environment and a great demonstration of team work from the clinical and research staff. Combining this unpredictability with conducting research projects from different disciplines (e.g. cardiology, toxicology etc.) makes a vibrant and dynamic place to work, where you constantly have the opportunity to develop yourself- an environment that Emma thrives on! In this post, she was proud to be the supportive piece of the EMERGE team jigsaw, knowing that we, as a team, are making an impact on future patient care.

In October 2019, Emma became the Research Project Manager for EMERGE where she aims to support project set up with the study co-ordinators, maintain a high standard of quality control among the research projects, and continue to support the EMERGE team in other project-admin tasks, to make today’s research become tomorrow’s practice. 


Trials

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

PRIEST

Pandemic Respiratory Infection Emergency System Triage

CERA

COVID-19 Emergency Response Assessment. A Professional Survey

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

ETNA

ETNA: Edinburgh Transient and Neurological attack: A Cohort Study

Patients frequently present with minor neurological symptoms where a diagnosis of transient ischaemic attack (TIA) or minor stroke is difficult to make positively or to exclude reasonably. For these patients, clinicians are uncertain whether they should: (a) reassure most patients that their symptoms are benign; (b) treat most patients with antiplatelet or other vascular prevention; or (c) stratify stroke risk further using clinical features or brain imaging.
This is important because clinical diagnosis is difficult. Mis-diagnosis is not infrequent and leads to harm from preventable recurrent stroke and costs to health systems from extra care and legal liabilities.
All ETNA participants will receive an MRI scan and the study aims to establish the feasibility and methods for a larger study of diagnostic utility of MR brain imaging and estimate the effects of MRI on clinician decision making.
This study has been recruiting in the Emergency Dept, inpatient wards and TIA clinics since August 2018. We aim to recruit 270 participants and have almost reached our target!

Read more

ETNA

TARGET-CTCA Trial

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

EMBOL1 Study

A Performance Evaluation of The Lumiradx Point of Care D Dimer Assay AS AN Aid in the Diagnosis and Assessment of VTE (EMBOL1)

EHA Study

EHA - Epidemiological analysis for the Hereditary Angioedema Disease is an international, multicentre, epidemiological study that aims to explore the feasibility of a new Dried Blood Spot (DBS) filtercard-based screening algorithm and thereby the prevalence of the Hereditary Angioedema.

Read more

EHA Study

EHA - Epidemiological analysis for the Hereditary Angioedema Disease

Minimal Unit Pricing Study (MUP)

Assessing the impact of the Minimum Unit Pricing

Read more

Minimal Unit Pricing Study (MUP)

Assessing the impact of the Minimum Unit Pricing

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)